Antiplatelet therapy in secondary prevention of non‑embolic ischaemic stroke

Czech version

Authors: Štefan Alušík ¹; Zoltán Paluch ²
Authors‘ workplace: Katedra vnitřního lékařství IPVZ Praha ¹; Ústav farmakologie 2. LF UK Praha ²
Published in: Vnitř Lék 2020; 66(8): 501-506
Category:

Overview

The authors address the topic of antiplatelet therapy after a non-cardioembolic ischaemic stroke. They discuss some controversial issues in therapy such as monotherapy versus combination therapy, short-term versus long-term therapy and whether current therapy should be modified or continued in the event a patient has experienced a stroke. Other outstanding issues dealt with include e.g., the risk of such therapy in patients developing cerebral microbleeds. While consensus has been reached by experts regarding the utility of dual therapy in the initial period, divergent opinions exist as to the selection of drugs and therapy duration. Definition of the optimal strategy is hindered by the lack of evidence and robust data from clinical trials.

Keywords:

acetylsalicylic acid – clopidogrel – dipyridamole – dual therapy – monotherapy.

Sources

1. Amarenco P, Lavallee PC, Labreuche J, et al. One‑year risk of stroke after transient ischemic attack or minor stroke. N Engl J Med 2016; 374: 1533–1542.

2. Zhang J, Yang Y, Sun H, et al. Hemorrhagic transformation after cerebral infarction: current concepts and challenges. Ann Transl Med 2014; 8: 81.

3. Royal College of Physicians. National clinical guideline for stroke. Prepared by the Intercollegiate Stroke Working Party. 5th ed.2016.

4. NICE guideline: Stroke and transient ischaemic attack in over 16 s: diagnosis and initial management (NG 128). Dostupné z WWW: https://www.nice.org.uk/guidance/ng128

5. Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 2018; 392: 387–399.

6. Rothwell PM, Algra A, Chen Z, et al. Effects of aspirin on risk and severity of early recu‑ rrent stroke after transient ischaemic attack and ischaemic stroke: time‑course analysis of randomised trials. Lancet 2016; 388: 365–375.

7. No author listed. Minor ischaemic stroke and antiplatelet drugs. Very little advantage from adding clopidogrel to aspirin. Prescrire Int 2019; 28: 77.

8. Karetová D, Bultas J. Cilostazol. Remedia 2014; 24: 441–449.

9. Shi L, Pu J, Xu L, et al. The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population- an updated meta‑analysis. BMC Neurology 2014; 14: 251.

10. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13.

11. ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665–1673.

12. Sacco RL, Diener HC, Yusuf S, et al. PRoFESS Study Group. Aspirin and extended‑release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238–1251.

13. Wang MT, Liang HL, Hung CC, et al. Combination Therapy with Dipyridamole and Clopidogrel for Secondary Stroke Prevention in Aspirin‑Intolerant Patients After Myocardial Infarction: Results of a Nationwide Case‑Control Study. CNS Drugs 2019; 33: 175–185.

14. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706–1717.

15. Wang Y, Wang Y, Zhao X, et al. CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013; 369: 11–19.

16. Johnston SC, Easton JD, Farrant M, et al. Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, POINT Investigators. Clopidogrel and Aspirin in Acute Ischemic Stroke and High‑Risk TIA. N Engl J Med 2018; 379: 2015–2025.

17. The SPS3 Investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012; 367: 817–825.

18. Diener HC, Bogousslavsky J, Brass LM, et al. MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high‑risk patients (MATCH): randomised, double‑blind, placebo‑controlled trial. Lancet 2004; 364: 331–337.

19. Bath PM, Woodhouse LJ, Appleton JP, et al. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open‑label, phase 3 superiority trial. Lancet 2018; 391: 850–859.